Top

Published in:

22-07-2022 | Chronic Myeloid Leukemia | Research

Clinical features, diagnosis, and management of dasatinib-induced nephrotic syndrome

Authors: Yang He, Weijin Fang, Zuojun Li, Chunjiang Wang

Published in: Investigational New Drugs | Issue 5/2022

Summary

Knowledge of dasatinib-induced nephrotic syndrome is largely based on case reports. The clinical features of dasatinib-induced nephrotic syndrome are unknown. We collected case reports of 25 patients with nephrotic syndrome and analyzed their clinical characteristics. Overall, the onset of nephrotic syndrome ranged from 10 days to 5 years after dasatinib administration. Nine patients (36.0%) had clinical symptoms, mainly periorbital edema and lower-extremity edema. Serum albumin ranged from 1.2 g/dL to 3.7 g/dL in 10 patients (38.5%). The 24-h urine protein values ranged from 3.54 g/day to 118 g/day. Kidney biopsy of 13 patients (52.0%) mainly showed focal foot process effacement, mesangial hyperplasia, endothelial cell damage and focal segmental glomerulosclerosis. Proteinuria resolved or recovered after dasatinib discontinuation or dose reduction or switching to other tyrosine kinase inhibitors (TKIs).

Rossari F, Minutolo F, Orciuolo E (2008) Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. J Hematol Oncol 11(1):84. https://doi.org/10.1186/s13045-018-0624-2CrossRef

Levêque D, Becker G, Bilger K, Natarajan-Amé S (2020) Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib. Clin Pharmacokinet 59(7):849–856. https://doi.org/10.1007/s40262-020-00872-4

Montero JC, Seoane S, Ocaña A, Pandiella A (2011) Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res 17(17):5546–5552. https://doi.org/10.1158/1078-0432.CCR-10-2616CrossRefPubMed

Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Brümmendorf TH, Kantarjian HM, Hochhaus A, Rousselot P, Mohamed H et al (2014) Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood 123(15):2317–2324. https://doi.org/10.1182/blood-2013-10-532341CrossRefPubMedPubMedCentral

Moslehi JJ, Deininger M (2015) Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. J Clin Oncol 33(35):4210–4218. https://doi.org/10.1200/JCO.2015.62.4718CrossRefPubMedPubMedCentral

Amrein PC, Attar EC, Takvorian T, Hochberg EP, Ballen KK, Leahy KM, Fisher DC, Lacasce AS, Jacobsen ED, Armand P et al (2011) Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 17(9):2977–2986. https://doi.org/10.1158/1078-0432.CCR-10-2879CrossRefPubMedPubMedCentral

Mahalingasivam V, Booth J, Sheaff M, Yaqoob M (2018) Nephrotic syndrome in adults. Acute Med 17(1):36–43PubMed

Mandac Rogulj I, Matišić V, Arsov B, Boban L, Juginović A, Molnar V, Primorac D (2019) Dasatinib-induced nephrotic syndrome: a case of phenoconversion. Croat Med J 60(3):250–254. https://doi.org/10.3325/cmj.2019.60.250CrossRefPubMedPubMedCentral

Wallace E, Lyndon W, Chumley P, Jaimes EA, Fatima H (2013) Dasatinib-induced nephrotic-range proteinuria. Am J Kidney Dis 61(6):1026–1031. https://doi.org/10.1053/j.ajkd.2013.01.022CrossRefPubMed

10.

Ruebner RL, Copelovitch L, Evageliou NF, Denburg MR, Belasco JB, Kaplan BS (2014) Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature. Pediatr Nephrol 29(5):863–869. https://doi.org/10.1007/s00467-013-2696-0CrossRefPubMed

11.

Lim YT, Kim YJ, Park YH, Hah JO, Lee JM (2016) A Case of Dasatinib-Induced Nephrotic Syndrome in a Child with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. Yonsei Med J 57(2):532–533. https://doi.org/10.3349/ymj.2016.57.2.532CrossRefPubMedPubMedCentral

12.

Ersoy Yesil E, Sit D, Kayabasi H, Zerenler Gursoy F, Demirbas MB, Ocak Serin S (2021) A case of dasatinib-induced focal segmental glomerulosclerosis in a patient with Philadelphia chromosome positive chronic myeloid leukemia. Nephrol Ther 17(1):53–56. https://doi.org/10.1016/j.nephro.2020.09.007CrossRefPubMed

13.

ElShaer A, Almasry M, Alawar M, Masoud H, El Kinge AR (2021) Dasatinib-Induced Nephrotic Syndrome: A Case Report. Cureus 13(12):e20330. https://doi.org/10.7759/cureus.20330CrossRefPubMedPubMedCentral

14.

Hirano T, Hashimoto M, Korogi Y, Tsuji T, Miyanaka K, Yamasaki H, Tsuda H (2016) Dasatinib-induced nephrotic syndrome. Leuk Lymphoma 57(3):726–727. https://doi.org/10.3109/10428194.2015.1075020CrossRefPubMed

15.

Ochiai S, Sato Y, Minakawa A, Fukuda A, Fujimoto S (2019) Dasatinib-induced nephrotic syndrome in a patient with chronic myelogenous leukemia: a case report. BMC Nephrol 20(1):87. https://doi.org/10.1186/s12882-019-1273-6CrossRefPubMedPubMedCentral

16.

Koinuma K, Sakairi T, Watanabe Y, IIzuka A, Watanabe M, Hamatani H, Nakasatomi M, Ishizaki T, Ikeuchi H, Kaneko Y, Hiromura K (2020) A case of long-term dasatinib-induced proteinuria and glomerular injury. CEN Case Rep 9(4):359–364. https://doi.org/10.1007/s13730-020-00484-8CrossRefPubMedPubMedCentral

17.

Kawaguchi H, Tamura Y, Suzuki S, Asano-Murakoshi T, Nonoyama S (2017) Cytomegalovirus infection- and dasatinib-induced proteinuria in Ph+ALL. Pediatr Int 59(6):740–741. https://doi.org/10.1111/ped.13251CrossRefPubMed

18.

De Luca ML, Carmosino I, Stefanizzi C, Campanelli M, De AF, Cesini L, Latagliata R, Alimena G (2016) Nephrotic Proteinuria Developed under Dasatinib Treatment in a Patient with Chronic Myeloid Leukemia: A Case Report and Review of the Literature. Ann Hematol Oncol 3(8):1106

19.

Piscitani L, Sirolli V, Di Liberato L, Morroni M, Bonomini M (2020) Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations. Int J Mol Sci 21(14):4878. https://doi.org/10.3390/ijms21144878CrossRefPubMedCentral

20.

Stanchina M, McKinnell Z, Park JH, Stein EM, Cai SF, Taylor J (2020) BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon. Leuk Res Rep 14:100211. https://doi.org/10.1016/j.lrr.2020.100211CrossRefPubMedPubMedCentral

21.

Li GH, Liu C, Qin WW, Zhou NC, Guo HP, Yan XQ, Ji YR, Chen Y, Liu L, Liang YM (2021) Dasatinib-induced massive proteinuria: a case report. Zhonghua Xue Ye Xue Za Zhi. 42(8):692. Chinese. https://doi.org/10.3760/cma.j.issn.0253-2727.2021.08.017

22.

Chow C, Abraham S (2015) Dasatinib induced chylothorax and nephrotic syndrome in a pediatric patient.Pediatric Blood and Cancer 62(Suppl.2):S71

23.

Loi V, Lepori N, Floris M, Asunis AM, Angioi A, Cao R, Atzeni A, Piras D, Cabiddu G, Pani A (2018) Dasatinib-associated FSGS: A case report. J Am Soc Nephrol 29:abstr 808

24.

Koshida T, Suzuki H, Kihara M, Nogi C, Suzuki Y (2017) Nephrotic syndrome in dasatinib-treated patients with chronic myeloid leukemia. J Am Soc Nephrol 28:abstr 410

25.

Muller-Hansma AHG, van der Lugt J, Zwaan CM (2017) Nephrotic syndrome under treatment with dasatinib: be aware of a possible adverse drug reaction. Neth J Med 75(10):428–431PubMed

26.

Orth SR, Ritz E (1998) The nephrotic syndrome. N Engl J Med 338(17):1202–1211. https://doi.org/10.1056/NEJM199804233381707CrossRefPubMed

27.

Calizo RC, Bhattacharya S, van Hasselt JGC, Wei C, Wong JS, Wiener RJ, Ge X, Wong NJ, Lee JJ, Cuttitta CM et al (2019) Disruption of podocyte cytoskeletal biomechanics by dasatinib leads to nephrotoxicity. Nat Commun 10(1):2061. https://doi.org/10.1038/s41467-019-09936-xCrossRefPubMedPubMedCentral

28.

Demetri GD, Lo Russo P, MacPherson IR, Wang D, Morgan JA, Brunton VG, Paliwal P, Agrawal S, Voi M, Evans TR (2009) Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res 15(19):6232–6240. https://doi.org/10.1158/1078-0432.CCR-09-0224CrossRefPubMed

29.

Wiggins RC (2007) The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int 71(12):1205–1214. https://doi.org/10.1038/sj.ki.5002222CrossRefPubMed

30.

Sato Y, Wharram BL, Lee SK, Wickman L, Goyal M, Venkatareddy M, Chang JW, Wiggins JE, Lienczewski C, Kretzler M, Wiggins RC (2009) Urine podocyte mRNAs mark progression of renal disease. J Am Soc Nephrol 20(5):1041–1052. https://doi.org/10.1681/ASN.2007121328CrossRefPubMedPubMedCentral

31.

Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH et al (2008) VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358(11):1129–1136. https://doi.org/10.1056/NEJMoa0707330CrossRefPubMedPubMedCentral

32.

Wada T, Ishimoto T, Nakaya I, Kawaguchi T, Sofue T, Shimizu S, Kurita N, Sasaki S, Nishiwaki H, Koizumi M et al (2021) A digest of the Evidence-Based Clinical Practice Guideline for Nephrotic Syndrome 2020. Clin Exp Nephrol 25(12):1277–1285. https://doi.org/10.1007/s10157-021-02098-5CrossRefPubMed

Title: Clinical features, diagnosis, and management of dasatinib-induced nephrotic syndrome
Authors: Yang He
Weijin Fang
Zuojun Li
Chunjiang Wang
Publication date: 22-07-2022
Publisher: Springer US
Keywords: Chronic Myeloid Leukemia
Tyrosine Kinase Inhibitors
Edema
Nephrotic Syndrome
Tyrosine Kinase Inhibitors
Bosutinib
Dasatinib
Imatinib
Nilotinib
Published in: Investigational New Drugs / Issue 5/2022
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-022-01288-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 5/2022

First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors

Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer

Phase I study of aflibercept in combination with docetaxel in Japanese patients with advanced solid malignancies

Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors

3D cell cultures, as a surrogate for animal models, enhance the diagnostic value of preclinical in vitro investigations by adding information on the tumour microenvironment: a comparative study of new dual-mode HDAC inhibitors

Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer